FDA grants approval of Crenessity (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia – Neurocrine Biosciences
Neurocrine Biosciences, Inc. announced the FDA approved Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years… read more.
